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Chronic  exposure  to high  levels  of  inorganic  arsenic  (iAs)  has been  associated  with  cancerous  and  non-
cancerous  health  effects,  including  cardiovascular  effects.  However,  the mechanism  for a presumed  toxic
effect of arsenic  on vascular  tissue  is  not  clear.  Our  working  hypothesis  is that  inorganic  trivalent  arsenic
and  its methylated  metabolites  react  with cysteine-containing  cellular  proteins  and  alter  their  func-
tion  leading  to adverse  events  such  as  cytotoxicity  or proliferation.  In this  study,  human  microvascular
endothelial  cells (HMEC1)  and  mouse  microvascular  endothelial  cells  (MFP-MVEC)  were  exposed  to
arsenite  (iAsIII), monomethylarsonous  acid  (MMAIII),  or  dimethylarsinous  acid  (DMAIII) for  72  h  to  eval-
uate  cytotoxicity,  and  for 24,  48  or 72 h to evaluate  cell  proliferation.  Both  cell  lines  showed  similar  LC50rsenic
ardiovascular
values,  from  0.1  to  2.4  M, for all three  trivalent  arsenicals.  The  endothelial  cells treated  with1  nM  to
1  M  concentrations  of  the  three  trivalent  arsenicals  did not  show  increased  cell proliferation  at  24, 48
or  72  h or  increased  rate  of  proliferation  at 72  h  of exposure.  Overall,  cytotoxicity  of trivalent  arseni-
cals  to microvascular  endothelial  cells  is  similar  to their  cytotoxicity  to  epithelial  cells, and  that  these
compounds  are  not  mitogenic.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
As a natural component of the earth’s crust, inorganic arsenic
iAs) is present in soil, water and food. Levels of inorganic arsenic
n drinking water vary, and in some parts of the world the levels are
s high as 900 ppb or higher [10]. Chronic exposure to high levels of
norganic arsenic has resulted in an increased risk of cancerous and
on-cancerous effects [10]. Whether health effects can result from
hronic exposure to low levels of iAs (<100 ppb) remains a matter
f scientiﬁc debate [10,32].Cardiovascular effects due to exposure to high levels of iAs,
enerally ≥100 ppb, are amongst the major investigated non-
ancerous effects [10,23,28]. The incidence of cardiovascular
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disease (CVD) risk factors, such as diabetes and hypertension, are
also suspected to be increased with exposure to high levels of iAs.
Increased prevalence of markers of atherosclerosis, such as carotid
plaques and increased thickness of carotid intima have been associ-
ated with exposure to high levels of iAs [23,24]. Risk of developing
microvascular changes, such as renal disease, neurological diseases,
and retinopathy were also reported to be greater with high iAs
arsenic exposures in drinking water, and the concurrent presence
of diabetes augmented these changes [7]. Most of the data are from
regions of high iAs water contamination. There is little evidence
with regard to any of the CVD-related effects at exposures to low
levels of iAs (<100 ppb in drinking water) [23,28,32].
Animal studies have produced conﬂicting results [5,6,28]. In
FVB female mice, chronic exposure to 100 ppb iAsIII in drinking
water for 22 weeks was shown to induce hypertension and cardiac
hypertrophy [25]. Chronic exposure to 200 or 1000 ppb iAs in drink-
ing water also showed development of atherosclerotic plaques
in the macrovasculature of ApoE-/- mice [20]. Mice administered
20 mg/kg of sodium arsenite in water showed increased vascular
leakage [5]. At a similar dose, iAs had anti-angiogenic activity in
solid tumor models by decreasing expression of vascular endothe-
lial growth factor (VEGF) [34].
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Soucy et al. [26] reported that vessel growth in ﬁbroblast growth
actor-2 (FGF-2)-containing Matrigel implants was increased in
ice exposed to 5–500 ppb iAs in drinking water for 5 or 20 weeks,
ut the response decreased with time. However, iAsIII alone did not
nduce neovascularization; rather, it enhanced the effect of FGF-2 in
he Matrigel. In addition, the concentration of FGF-2 in the Matrigel
as signiﬁcantly higher than normally occurs in mice or in humans.
The pathogenesis of atherosclerosis has traditionally fallen
nder two overarching hypotheses: one theory stresses inti-
al  cellular proliferation while the other premise emphasizes
ecurring thrombi organized over time into clinically signiﬁcant
laques [28]. Various cellular mechanisms for arsenic-induced
ffects on the microvasculature have been suggested [2,3,22,29],
ncluding increased vascular oxidative stress, increased vascular
nﬂammatory response, induction of endoplasmic reticulum stress,
ctivation of G-protein coupled receptor activation, and stimu-
ation of vascular redox signaling [29]. Pro- and anti-angiogenic
esponses have been reported when mouse aortic endothelial cells
ere exposed to high doses of iAs in vitro [22,29]. Stimulation of
ell proliferation by low concentrations of iAs has been observed
n endothelial cells, speciﬁcally, in porcine aortic endothelial cells
n vitro [2], human microvascular endothelial cells (HMEC1) [13],
nd human lung microvascular endothelial cells [17], possibly sec-
ndary to oxidative stress. However, observations of oxidative
tress in vitro secondary to exposure to arsenicals are not always
xpressed in a similar manner in vivo [10]. Furthermore, a recent
tudy showed that in Bangladesh, in a high arsenic exposed popula-
ion, an association with markers of oxidative stress was not found
14].
Liver sinusoidal defenestration was reported in a mouse model
reated with 10–250 ppb iAs in drinking water [30]. However, the
esponse in the mouse liver appeared to be transient, and further-
ore, none of the hepatic sequelae, such as steatosis, ﬁbrosis or
irrhosis, that usually are associated with these vascular changes
ere observed in longer term studies in mice [31,33].
The applicability to humans of these models in which the
ffects of iAs on the endothelium were evaluated, is questionable.
ouse models of cardiovascular abnormalities or other inﬂamma-
ory changes in general do not appear to be representative of the
isorders in humans [27,28] so that extrapolation of the results to
uman risk assessment must be made with caution.
Mammals metabolize inorganic arsenic to mono-, di- and tri-
ethylated compounds of pentavalent arsenic, with mono- and
imethylated compounds of trivalent arsenic formed as intermedi-
tes. Numerous studies have shown that the trivalent forms, iAsIII,
MAIII, and DMAIII are reactive and cytotoxic to several epithelial
ell types, in contrast to the corresponding pentavalent forms that
re not toxic [9]. Further, studies have shown that trivalent methy-
ated forms (MMAIII, DMAIII) are somewhat more cytotoxic than
AsIII to human keratinocytes, urothelial cells, and bronchial epithe-
ial cells, the target tissues for iAs-induced cancer [11]. A similar
oxicity pattern has been demonstrated for rat aortic macrovascular
ndothelial cells [15].
In the present studies, we examined the proliferative response
f mouse and human microvascular endothelial cells to the triva-
ent arsenicals (iAsIII, MMAIII and DMAIII) as well as the cytotoxicity
LC50) of the trivalent arsenicals in the same cells.
. Materials and methods
.1. Chemicals and reagentsSodium arsenite (NaAsO2, purity 99%) was purchased from
igma (St. Louis, MO). MMAIII and DMAIII were synthesized by
r. William Cullen (University of British Columbia, Vancouver,Reports 2 (2015) 833–837
Canada), and supplied as the di-iodide and mono-iodide, respec-
tively. The identity and purity of the chemicals were determined
by NMR  analysis at the University of British Columbia and accepted
without further testing. MMAIII and DMAIII were stored desiccated
in the dark at approximately 4 ◦C.
2.2. Cell culture
The human microvascular endothelial cell (HMEC1) line was
obtained from the Centers for Disease Control and Prevention
(Atlanta, GA). HMEC1s were isolated from human foreskin dermal
tissue and immortalized by the transfection of the transforming
protein, SV40 large T antigen [1]. The HMEC1 line was grown in
RPMI medium (Hyclone, Thermo Fisher Scientiﬁc, Rochester, NY)
containing fetal bovine serum (5% v/v) (Atlanta Biologicals, Atlanta,
GA), supplemented with 5 ml  L-glutamine (MediaTech, Herndon,
VA), 100 units/mL penicillin and 100 g/mL streptomycin (all from
Invitrogen, Grand Island, NY) at 37 ± 1 ◦C in an atmosphere of 95%
air and 5% CO2.
The mouse mammary fat pad microvascular endothelial cell line
(MFP MVEC) was created from cells isolated from the mammary
fat pad (MFP) tissue of two  female H-2Kb-ts-A58 mice (Immor-
tomice, Charles River Laboratories, Wilmington, MA)  [19]. Brieﬂy,
Immortomice carry a temperature-sensitive mutant of SV40 large
T antigen under the control of the H-2Kb promoter (activated
by interferon-), which can be used to conditionally immortalize
isolated primary cells when grown at the permissive tempera-
ture of 33 ◦C [16]. MFP  MVECs were cultured on 0.2% gelatin-
(Sigma–Aldrich, St. Louis, MO)  coated ﬂasks in DMEM (Hyclone
Laboratories, Logan, UT) supplemented with 2 mM GlutaMaxTM,
1 mM sodium pyruvate, 0.1 mM MEM  nonessential amino acids, 1x
MEM  vitamins, 100 units/mL penicillin, 100 g/mL streptomycin,
0.25 g/mL amphotericin B (FungizoneTM), 40 g/mL gentamicin
(all from Invitrogen, Grand Island, NY), and 10% heat-inactivated
fetal bovine serum (FBS) (Atlanta Biologicals) in an atmosphere of
95% air and 5% CO2 at 33 ◦C for routine expansion and at 37 ◦C for
at least 5 days before experiments.
2.3. Determination of cytotoxicity (LC50)
The number of cells required to be seeded on a 96-well plate to
reach approximately 80% conﬂuence at the end of 96 h of plating
with a change of medium at 24 h after seeding was  ﬁrst determined.
Cell viability was  determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were
exposed to varying concentrations (HMEC1, 0.1–50 M; MFP
MVEC, 0.005–50 M)  of trivalent arsenicals at 24 h after plating and
continued for 72 h. The cell viability after 72 h treatment was nor-
malized to control. The data were analyzed by non-linear regression
analysis (GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego, California, USA). The cytotoxic response of
the trivalent arsenicals was  compared based on the resulting LC50
values.
2.4. Determination of cell proliferation by ﬂow cytometry
The cells were plated in 6-well plates. To maximize the detec-
tion sensitivity, the cells were cultured in a low FBS-containing
medium (1% FBS for HMEC1, 2.5% for MFP-MVEC). First, the num-
ber of cells required to be seeded in low FBS-containing medium
that would reach 80% conﬂuence at the end of 72 h was  deter-
mined. The cells were seeded and immediately exposed to different
concentrations of trivalent arsenicals (HMEC1, 1–1000 nM; MFP-
MVEC, 1–500 nM). At 72 h after treatment, the cells were labeled
with bromodeoxyuridine (BrdU) for 1 h to incorporate into DNA
of cells. Cells were then harvested for ﬂow cytometry analysis as
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Table  1
LC50 values of trivalent arsenicals on microvascular endothelial cells.
Cell type LC50 (M)
iAsIII MMAIII DMAIII
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MFP-MVEC 1.4 0.12 0.61
er BD PharmingenTM BrdU ﬂow kit (BD Biosciences, San Jose, CA)
sing a ﬂow cytometer (FACSCaliburTM, BD Biosciences, San Jose,
A). Cellular DNA was labeled with 7-aminoactinomycin D (7-AAD)
nd stained with ﬂuorescent anti-BrdU antibody for ﬂow cytomet-
ic cell cycle analysis. The number of cells in G0/G1, S and G2/M
hases of the cell cycle were counted for at least 10,000 events. Cell
roliferation was determined using the percent of cells in S-phase
ndicated the proliferation of cells actively synthesizing DNA.
.5. Determination of cell proliferation by MTT  assay
The cells were plated in 96-well plates in low FBS-containing (1%
BS for both cell types) medium and allowed to acclimatize for 24 h,
ollowed by treatment with varying concentrations of arsenicals
1–500 nM). The cell survivability was determined at 24 h, 48 h and
2 h of arsenical treatment using the MTT  assay. Any increase in cell
umber was expected to increase the MTT  absorbance, and that was
ompared to control (1% FBS-containing media only) to determine
he effect of treatment. Regular medium containing appropriate
evels of FBS (5% for HMEC1 cells, 10% for MFP-MVECs) was used as
 positive control.
.6. Statistical analysis
Cell proliferation data obtained by ﬂow cytometry were ana-
yzed by one way analysis of variance followed by Dunnett’s test.
 values less than 0.05 were considered signiﬁcant. All statistical
nalyses were performed using Prism 5.03 (GraphPad Software, La
olla, CA).
. Results
.1. Cytotoxicity of trivalent arsenicals for microvascular
ndothelial cells
The LC50 values for HMEC1 cells were: 0.74 M for MMAIII,
.0 M for DMAIII, and 2.3 M for iAsIII; and for MFP-MVECs
ells: 0.12 M for MMAIII, 0.61 M for DMAIII and 1.4 M for iAsIII
Table 1). Both HMEC1 and MFP-MVECs cells were slightly more
ensitive to MMAIII compared to iAsIII or DMAIII. Lower concentra-
ions of iAsIII appeared to slightly increase the cell viability in both
ell types, with a greater effect observed in MFP-MVECs (Fig. 1).
Fig. 1. Cytotoxicity evaluation determined by MTT  assay of endothelial Fig. 2. Flow cytometry analysis for S phase of endothelial cells treated with trivalent
arsenicals for 72 h at concentrations ranging from 1 nM to 1000 nM.
3.2. Trivalent arsenicals and endothelial cell proliferation
3.2.1. Endothelial cell proliferation measured by ﬂow cytometry
Both HMEC1 and MFP-MVECs exposed to trivalent arsenicals
showed no increase in rate of cell proliferation measured at the
end of 72 h treatment (Fig. 2). Speciﬁcally, the trivalent arsenicals
did not increase the percent of cells in S-phase of the cell cycle as
measured by ﬂow cytometry..
3.2.2. Endothelial cell proliferation measured by MTT  assay
The effect of trivalent arsenicals on endothelial cell prolifera-
tion was also measured at 24, 48 and 72 h of treatment using the
MTT  assay (Fig. 3a and b). The MTT  assay indirectly represents the
number of living mitochondria, which correspond to the number of
living cells. None of the three trivalent arsenicals induced increased
cells exposed to trivalent arsenicals for 72 h to estimate the LC50.
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ndothelial cells.
ndothelial cell proliferation by this assay measured at any time
oint.
. Discussion
In the present study, none of the trivalent arsenicals increased
he rate of cell proliferation or showed a cell proliferation response
n either cell type. Importantly, this ﬁnding does not support arsenic
ausing CVD by means of endothelial cell proliferation.
Similar to earlier reports for epithelial cell types, MMAIII was rel-
tively more cytotoxic to both endothelial cell lines than DMAIII and
AsIII. In mouse cells, MMAIII was 5 fold more toxic than DMAIII and
1 fold more toxic than iAsIII, and in human cells MMAIII was 2 fold
ore toxic than DMAIII and 3 fold more toxic than iAsIII. The mouse
ndothelial cells were more sensitive, with lower LC50 values, for
he three trivalent arsenicals, and the human cells were more sen-
itive for iAsIII and MMAIII compared to the results of our previous
tudies in human urothelial 1T1 cells, human keratinocytes and
uman bronchial epithelial cells [8,11]. The LC50 of 2.3 M for
AsIII in HMEC1 cells is similar to the LC50 of 2.4 M reported by
raham-Evans et al. [13] who conducted a similar test using dif-
erent medium. In that study, endothelial cells were most sensitive
o iAsIII, with the lowest LC50 value compared to other cell types,
ncluding keratinocytes (HaCaT), melanocytes (CRL 1675), dendritic
ells, dermal ﬁbroblasts (CRL1904), and monocytes (TIB202).
None of the three test compounds caused an increase in the
ercent of endothelial cells in S-phase of either human or mouse at
ny concentration, ranging from nM range to M range for up to
2 h exposures. Similarly, there was no increase in cell viability at
4, 48 or 72 h with iAsIII, MMAIII or DMAIII treatment in a growth
inetics experiment, indicating no stimulation of cell proliferation.
owever, in the cytotoxicity assay, when viability was  measured
fter 72 h exposure to the trivalents, there was a slight increase in
ell viability (<15% in HMEC1, and <30% in MFP-MVECs) with lower
oncentrations of iAsIII. This is in contrast to the growth kinetics
utcome (Fig. 3) which did not show increased viability at 72 h.
he amount of FBS in the medium is the major difference between
hese two experiments. Low concentrations of iAsIII in low-FBS con-
aining medium did not stimulate cell proliferation (Fig. 3). Also,
either MMAIII nor DMAIII increased cell numbers (Fig. 3). There
as a statistically signiﬁcant decrease in the number of S-phase
ells with MMAIII treatment in MFP-MVECs at 50 and 500 nM con-
entrations. MF-MVECs are most sensitive to MMAIII compared totrivalent arsenicals for 24, 48 or 72 h. (A) HMEC1 endothelial cells, (B) MFP MVEC
AsIII or DMAIII (Fig. 1, Table 1) and it is likely that MMAIII is cytotoxic
at these concentrations.
The ﬁndings of the current study, which show that trivalent
arsenicals do not induce endothelial cell proliferation in vitro are
in contrast to other studies which have suggested a weak bipha-
sic response in HMEC1 cells [13] and porcine aortic endothelial
cells [2,3]: a proliferative response at low concentrations of iAsIII
and a cytotoxic response as the concentration of iAsIII is increased.
These contrasting results may  be due to differences in the media
used to grow HMEC1 cells or in macrovascular or microvascular
cells in the porcine experiments. Graham-Evans et al. [13] used
endothelial basal medium, whereas RPMI-based medium was  used
in our study. Furthermore, there were differences in the amount of
added growth factors in the medium. Barchowsky et al. [2] showed
that iAsIII slightly increased the rate of proliferation only in con-
ﬂuent cells but not in cells that were exponentially growing. In
the current experiment, the number of cells seeded were approx-
imately 80% conﬂuence at the end of 72 h and therefore, the cells
were growing throughout the experiment. Furthermore, endothe-
lial cells from different tissues have different biological properties
and likely respond to chemicals, such as trivalent arsenicals, differ-
ently, or even not responding at all.
A weak biphasic (hormetic) response has been observed in
HMEC1 cells with other agents, such as Au@Fe3O4 Janus parti-
cles [18] and statins [4]. The hormetic response could represent
an adaptive process of the system in response to the stressor by
increasing expression of cell protective signaling, and is known to
occur for a large number of cytotoxic agents in multiple cancer cell
lines [4,21]. Cell protective signaling includes NF-kB signaling, Nrf2,
kinases, including deacetylases, which in turn stimulate growth
factor production [21]. This might explain why Barchowsky et al.
[2] reported involvement of NF-kB signaling in the low-dose iAsIII-
induced increase in the rate of cell proliferation in porcine aortic
endothelial cells.
These various responses have all been investigated in vitro. How-
ever, it is unknown what the effect will be in vivo in animals or in
humans.
The results of our current study do not support a direct mito-
genic effect by trivalent arsenicals as the basis for endothelial
effects of arsenicals at any concentration. In vitro, our results sug-
gest that at sufﬁciently high concentrations (>0.1 M)  trivalent
arsenicals can produce endothelial cytotoxicity. In vitro, this results
in cell death. In vivo, the cell damage, including cell death, would
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he consequences could be the various cardiovascular effects asso-
iated with exposure to high levels of inorganic arsenic.
Whether or not an endothelial and consequent cardiovascular
ffect is produced in vivo in animal models or in humans will be
ependent on the concentrations of the trivalent arsenicals in the
ndothelial cells being greater than the minimal amount required
o produce an effect. Thus, a threshold is involved. To achieve tis-
ue concentrations of trivalent arsenicals in humans >0.1 M,  the
pparent threshold for a biologic effect in epithelial, endothelial
nd other cell types [10,12], requires exposure to inorganic arsenic
n drinking water of approximately 100 ppb [10].
Multiple epidemiological studies have associated exposure to
igh levels of arsenic (≥100 ppb in drinking water) with cardio-
ascular changes [20,25,29,32]. However, evidence for vascular
hanges in humans induced by exposure below 100 ppb in drinking
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